Irbesartan Aurobindo

Irbesartan, the active ingredient in Irbesartan Aurobindo, is an Angiotensin II receptor blocker presented as an oral tablet for systemic use. It is prescribed to manage high blood pressure and to protect kidney function in patients with diabetes‑related nephropathy.

GNH USA supplies Irbesartan Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan is used to treat conditions related to the renin‑angiotensin system, primarily hypertension and diabetic kidney disease.

- Hypertension: lowers elevated blood pressure, reducing the risk of stroke and heart attack. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes, helping preserve renal function. - Proteinuria: reduces urinary protein excretion associated with chronic kidney disease.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Upper respiratory infection: symptoms such as sore throat or nasal congestion. - Nausea: mild stomach upset or urge to vomit. - Diarrhea: loose stools occurring intermittently.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing. - Hyperkalemia: elevated potassium levels that can cause cardiac rhythm disturbances. - Acute renal impairment: sudden decline in kidney function, indicated by rising creatinine. - Hepatic injury: signs of liver damage such as jaundice or abnormal liver enzymes. - Severe hypotension: markedly low blood pressure leading to fainting or shock.

Patients should be monitored regularly while taking Irbesartan.

- Blood pressure monitoring: check regularly to ensure therapeutic control. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Electrolyte surveillance: monitor potassium levels, especially if combined with potassium‑sparing agents. - Pregnancy avoidance: discontinue if pregnancy is confirmed or planned. - Caution with potassium supplements: avoid concurrent high‑potassium intake. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines that affect the renin‑angiotensin system or electrolyte balance.

Major Interactions (Avoid): - Aliskiren (in diabetes): combined use can increase renal risk. - ACE inhibitors or other ARBs: dual blockade may cause severe hypotension or renal failure. - Potassium supplements/high‑potassium diet: risk of hyperkalemia. - NSAIDs (e.g., ibuprofen): may impair renal function. - Lithium: increased lithium levels and toxicity.

Moderate Interactions (Monitor Closely): - Potassium‑sparing diuretics (e.g., spironolactone): watch for elevated potassium. - CYP2C9 inhibitors (e.g., fluconazole): may raise Irbesartan concentrations. - CYP3A4 inducers (e.g., rifampin): may reduce drug exposure. - Other antihypertensives: additive blood‑pressure‑lowering effect. - NSAIDs (non‑major use): monitor renal parameters.